gefitinib has been researched along with aee 788 in 11 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (aee 788) | Trials (aee 788) | Recent Studies (post-2010) (aee 788) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 83 | 3 | 34 |
| Protein | Taxonomy | gefitinib (IC50) | aee 788 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.002 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.004 | |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | 0.0153 | |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | 0.74 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.059 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.002 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.077 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boggon, TJ; Eck, MJ; Greulich, H; Li, Y; Meyerson, M; Woo, MS; Yun, CH | 1 |
| Eck, MJ; Greulich, H; Mengwasser, KE; Meyerson, M; Toms, AV; Wong, KK; Woo, MS; Yun, CH | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Blüthner, T; Caca, K; Feisthammel, J; Kamenz, T; Kluge, A; Mössner, J; Tannapfel, A; Wiedmann, M | 1 |
| Marais, R; Niculescu-Duvaz, D; Springer, C; Whittaker, S | 1 |
| Baker, CH; Bekele, N; Fidler, IJ; Herbst, RS; Langley, RR; O'Reilly, MS; Onn, A; Tang, XM; Tsan, RZ; Wu, W | 1 |
| Coveney, PV; Wan, S | 1 |
| Lamorte, G; Meco, D; Pallini, R; Patriarca, V; Riccardi, R; Servidei, T; Trivieri, N; Vellone, VG; Zannoni, GF | 1 |
| Bollu, LR; Gao, G; Huang, WC; Hung, MC; Ren, J; Su, F; Weihua, Z; Xu, L | 1 |
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
11 other study(ies) available for gefitinib and aee 788
| Article | Year |
|---|---|
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
Topics: Adenosine Triphosphate; Animals; Crystallography, X-Ray; Drug Resistance; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Insecta; Kinetics; Mutation; Protein Conformation; Quinazolines | 2008 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Topics: Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; DNA, Complementary; DNA, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Purines; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
The EGF receptor Hokey-Cokey.
Topics: Antineoplastic Agents; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phosphorylation; Purines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays | 2007 |
Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs.
Topics: Computer Simulation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Purines; Quinazolines | 2011 |
Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Proliferation; Child; Ependymoma; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoenzyme Techniques; In Vitro Techniques; Mice; Neoplastic Stem Cells; Purines; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Male; Phosphorylation; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Sodium-Glucose Transporter 1 | 2013 |
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |